Tecentriq Improves Progression-Free Survival in Advanced Bladder Cancer

By Reuters Staff

August 07, 2019

ZURICH (Reuters) - Roche Holding said Tecentriq (atezolizumab) combined with platinum-based chemotherapy reduced the risk of disease progression in patients with previously untreated locally advanced or metastatic urothelial carcinoma, the Swiss pharma company said on Monday.

The company also reported that a positive trend in the coprimary endpoint of overall survival was noted at the interim analysis, but the data are not yet mature.

The 1213 patients in the multicenter, partially blinded phase III IMvigor130 study were randomized to receive atezolizumab alone; atezolizumab combined with platinum-based chemotherapy comprising gemcitabine with either cisplatin or carboplatin; or the same chemotherapy option combined with placebo.

Roche said it would share the data with the U.S. Food and Drug Administration and the European Medicines Agency.